56.94 +0.18 (0.32%)
After hours: 4:37PM EST
|Bid||50.00 x 100|
|Ask||79.93 x 100|
|Day's Range||55.79 - 57.91|
|52 Week Range||45.31 - 71.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.71|
In January 2018, the U.S. FDA (Food and Drug Administration) accepted Novartis’s (NVS) supplemental biologics license application (or SBLA) for Kymriah suspension for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL) who are not candidates for autologous stem cell transplant (or ASCT). The U.S. FDA granted Novartis’s sBLA for priority review. Also, the European Medicines Agency (or EMA) granted accelerated assessment to the marketing authorization application (or MAA) for Novartis’s Kymriah for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL) and also for adults with relapsed or refractory DLBCL who are not candidates for ASCT.
European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Seattle Genetics, Inc. reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that the European Commission has extended the current conditional marketing authorization for ADCETRIS to include the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma after at least one prior systemic therapy.
Seattle Genetics, Inc. announced today that it will report its fourth quarter and year 2017 financial results on Tuesday, February 6, 2018 after the close of financial markets.
Seattle Genetics, Inc. highlighted today the progress of its pipeline of antibody-drug conjugates at the 36th Annual J.P. Morgan Healthcare Conference. Through both internal efforts and that of its collaborators, the company’s ADC technology is being employed in more than 20 programs in clinical trials, including multiple late-state development programs across hematologic malignancies and solid tumors....
Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
Seattle Genetics' supplemental Biologics License Application for the label expansion of its lymphoma drug, Adcetris, was accepted by the FDA and granted priority review.
Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing a supplemental Biologics License Application for ADCETRIS in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Seattle Genetics, Inc. Here are 5 ETFs with the largest exposure to SGEN-US. Comparing the performance and risk of Seattle Genetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Seattle Genetics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Seattle Genetics, Inc. – ImmunoGen, Inc., Celldex Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., Pfizer Inc. and Progenics Pharmaceuticals, Inc. (IMGN-US, CLDX-US, SPPI-US, PFE-US and PGNX-US) that have also reported ... Read more (Read more...)
Seattle Genetics, Inc. announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 10:30 a.m.
NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...
Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of ADCETRIS and Opdivo in relapsed or refractory classical Hodgkin lymphoma at the 59th American Society of Hematology Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017.
Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology annual meeting on Sunday, December 10, 2017.
Seattle Genetics, Inc. today highlighted final five-year survival results from a phase 1 clinical trial evaluating ADCETRIS in mature T-cell lymphoma at the 59th American Society of Hematology Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017.
Seattle Genetics, Inc. today highlighted updated results from the phase 3 ALCANZA clinical trial evaluating ADCETRIS in CD30-expressing cutaneous T-cell lymphoma at the 59th American Society of Hematology Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017.